ABD Promos, February 2013, Vol. 13, no.2

The ABD Promos Newsletter is produced monthly and details Division announcements, holiday schedules, broker promotions and a newly listed codes clipout section, which is formatted to be stapled into the Iowa Liquor Quarterly Spirits Price Book.

ABD Promos, March 2013, Vol. 13, no. 3

The ABD Promos Newsletter is produced monthly and details Division announcements, holiday schedules, broker promotions and a newly listed codes clipout section, which is formatted to be stapled into the Iowa Liquor Quarterly Spirits Price Book.

ABD Promos, April 2013, Vol. 13, no.4

The ABD Promos Newsletter is produced monthly and details Division announcements, holiday schedules, broker promotions and a newly listed codes clipout section, which is formatted to be stapled into the Iowa Liquor Quarterly Spirits Price Book.

ABD Promos, May 2013, Vol. 13, no. 5

The ABD Promos Newsletter is produced monthly and details Division announcements, holiday schedules, broker promotions and a newly listed codes clipout section, which is formatted to be stapled into the Iowa Liquor Quarterly Spirits Price Book.

ABD Promos, June 2013, Vol. 13, no. 6

The ABD Promos Newsletter is produced monthly and details Division announcements, holiday schedules, broker promotions and a newly listed codes clipout section, which is formatted to be stapled into the Iowa Liquor Quarterly Spirits Price Book.

ABD Promos, July 2013, Vol. 13, no. 7

The ABD Promos Newsletter is produced monthly and details Division announcements, holiday schedules, broker promotions and a newly listed codes clipout section, which is formatted to be stapled into the Iowa Liquor Quarterly Spirits Price Book.

ABD Promos, August 2013, Vol. 13, no. 8

The ABD Promos Newsletter is produced monthly and details Division announcements, holiday schedules, broker promotions and a newly listed codes clipout section, which is formatted to be stapled into the Iowa Liquor Quarterly Spirits Price Book.

ABD Promos, September 2013, Vol. 13, no. 9

The ABD Promos Newsletter is produced monthly and details Division announcements, holiday schedules, broker promotions and a newly listed codes clipout section, which is formatted to be stapled into the Iowa Liquor Quarterly Spirits Price Book.

Friday Facts, December 13, 2013, Vol. 195

Bureau of Nutrition and Health Promotion part of the Iowa Department of Public Health produces of weekly newsletter about the Iowa WIC Program for the State of Iowa citizen.

A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites

PURPOSE: As no curative treatment for advanced pancreatic and biliary cancer with malignant ascites exists, new modalities possibly improving the response to available chemotherapies must be explored. This phase I study assesses the feasibility, tolerability and pharmacokinetics of a regional treatment of gemcitabine administered in escalating doses by the stop-flow approach to patients with advanced abdominal malignancies (adenocarcinoma of the pancreas, n = 8, and cholangiocarcinoma of the liver, n = 1). EXPERIMENTAL DESIGN: Gemcitabine at 500, 750 and 1,125 mg/m(2) was administered to three patients at each dose level by loco-regional chemotherapy, using hypoxic abdominal stop-flow perfusion. This was achieved by an aorto-caval occlusion by balloon catheters connected to an extracorporeal circuit. Gemcitabine and its main metabolite 2',2'-difluorodeoxyuridine (dFdU) concentrations were measured by high performance liquid chromatography with UV detection in the extracorporeal circuit during the 20 min of stop-flow perfusion, and in peripheral plasma for 420 min. Blood gases were monitored during the stop-flow perfusion and hypoxia was considered stringent if two of the following endpoints were met: pH </= 7.2, pO(2) nadir ratio </=0.70 or pCO(2) peak ratio >/=1.35. The tolerability of this procedure was also assessed. RESULTS: Stringent hypoxia was achieved in four patients. Very high levels of gemcitabine were rapidly reached in the extracorporeal circuit during the 20 min of stop-flow perfusion, with C (max) levels in the abdominal circuit of 246 (+/-37%), 2,039 (+/-77%) and 4,780 (+/-7.3%) mug/ml for the three dose levels 500, 750 and 1,125 mg/m(2), respectively. These C (max) were between 13 (+/-51%) and 290 (+/-12%) times higher than those measured in the peripheral plasma. Similarly, the abdominal exposure to gemcitabine, calculated as AUC(t0-20), was between 5.5 (+/-43%) and 200 (+/-66%)-fold higher than the systemic exposure. Loco-regional exposure to gemcitabine was statistically higher in presence of stringent hypoxia (P < 0.01 for C (max) and AUC(t0-20), both normalised to the gemcitabine dose). Toxicities were acceptable considering the complexity of the procedure and were mostly hepatic; it was not possible to differentiate the respective contributions of systemic and regional exposures. A significant correlation (P < 0.05) was found between systemic C (max) of gemcitabine and the nadir of both leucocytes and neutrophils. CONCLUSIONS: Regional exposure to gemcitabine-the current standard drug for advanced adenocarcinoma of the pancreas-can be markedly enhanced using an optimised hypoxic stop-flow perfusion technique, with acceptable toxicities up to a dose of 1,125 mg/m(2). However, the activity of gemcitabine under hypoxic conditions is not as firmly established as that of other drugs such as mitomycin C, melphalan or tirapazamine. Further studies of this investigational modality, but with bioreductive drugs, are therefore warranted first to evaluate the tolerance in a phase I study and later on to assess whether it does improve the response to chemotherapy.

2013 Elder Abuse Task Force Final Report Pursuant to Senate File 446, Section 50, December 13, 2013

Per the guidance of the Legislative Elder Abuse Prevention and Intervention Interim Committee, a prioritization of the implementation recommendations and proposed legislation are below listed in the order determined in the 2012 Elder Abuse Task Force Report.

FY'13 Biodiesel Fuel Revolving Fund Expenditures Report, January 27, 2014

Pursuant to Iowa Code section 307.20, the biodiesel fuel revolving fund (Fund) was created and is to be used to purchase biodiesel fuel for use in the Department of Transportation's vehicles. The act directed that the Fund receive money from the sale of EPAct credits banked by the DOT on the effective date of the act, moneys appropriated by the General Assembly, and any other moneys obtained or accepted by the DOT for deposit in the Fund. This report is of the expenditures made from the Fund during FY 2013.

Farm Families Alive and Well, March 2007, Vol. 13, no. 2

News from Iowa’s Center for Agricultural Safety and Health (I-CASH)

Farm Families Alive and Well, Vol. 13, issue 1, December 2006

News from Iowa’s Center for Agricultural Safety and Health (I-CASH)